The BIOSECURE Act was passed with a large bipartisan majority in the House in 2024 and now awaits action in the Senate in 2025. Passage of the Act would be a significant first step in protecting ...

Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation created a window of reprieve for the affected biotech companies.

The future of the BIOSECURE Act was made more uncertain over the weekend after senators left the legislation out of a pivotal defence budget bill. The omission means the act, which intends to ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

As recently as five years ago, China was a bit player in biotechnology as their percentage of worldwide clinical trial activity was in the single digits. Over the last five years, China’s share of the ...

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

Aragen, based in Hyderabad, says it will use the funds to boost manufacturing capacity for newer treatment modalities, such ...